Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

It's evident that big pharma giant Moderna (NASDAQ: MRNA) is going through troubled times. Worse, it's dragging other big Pharma giants with it.

The Big Pharma Giants Are Down

Is Moderna a Bad-News Buy?

Is the next phase of revenue growth just ahead?

3 Things You Need to Know About Moderna's Post-Pandemic Revenue

Pfizer

Some positive news sent their share prices higher, but biotech companies will need to find other ways to make money.

Did Vaccine Stocks Just Get Their Last Boost?

mRNA-1273.222 targets BA.4/BA.5 Omicron subvariants and follows the approval of mRNA-1273.214 (SPIKEVAX Bivalent) in Canada, which targets the Omicron BA.1 subvariant CAMBRIDGE, MA / ACCESSWIRE / November 4, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has authorized the use of its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, as a booster dose for active immunization against COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older. The 50 µg booster dose of mRNA-1273.222 includes 25 µg of mRNA encoding for the spike protein of BA.4/BA.5 and 25 µg encoding for the original strain of the SARS-CoV-2 virus.

Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Activision Blizzard

CoStar Group

First Solar

Garmin

Incyte

Regeneron Pharmaceuticals

Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way.

7 Cash-Rich Stocks to Buy for Peace of Mind

Covid vaccine stocks surged Friday after a new study suggested an added benefit of the updated omicron-targeting boosters. The post This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters appeared first on Investor's Business Daily.

This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters

Is Moderna stock a buy or a sell after cutting its 2022 outlook for Covid vaccines just as Pfizer, BioNTech unveil promising booster news? The post Is Moderna Stock A Buy Or A Sell As It Yo-Yos On An Influx Of Covid News?

Is Moderna Stock A Buy Or A Sell As It Yo-Yos On An Influx Of Covid News?

This drugmaker's bottom line fell down a deep hole in the third quarter and investors want to know if it's time to run for the hills.

Moderna's Earnings Collapsed. Time to Sell?

COVID-19 vaccine maker Moderna's shares fell on Thursday following the release of the company's third-quarter earnings, which showed a decline in revenue.

Moderna stock tumbles after quarterly earnings show revenue declines

Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.

Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook

Moderna, Inc. (NASDAQ:MRNA ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Lavina Talukdar – Head-Investor Relations Stéphane Bancel – Chief Executive Officer Stephen Hoge – President Arpa Garay – Chief Commercial Officer Jamey Mock – Chief Financial Officer Conference Call Participants Salveen Richter – Goldman Sachs Matthew Harrison – Morgan Stanley Edward Tenthoff – Piper Sandler Michael Yee – Jefferies Gena Wang – Barclays Tara Bancroft – Cowen Jessica Fye – J.P. Morgan Geoff Meacham – Bank of America Eliana Merle – UBS Joseph Stringer – Needham Operator Good morning.

Moderna, Inc. (MRNA) Q3 2022 Earnings Call Transcript

The global tally of COVID-19 cases fell 17% in the week through Oct. 30 from the previous week, while the death toll fell 5%, the World Health Organization said in its weekly update on the virus.

Global tally of COVID cases and deaths continues to fall; Moderna cuts vaccine-sales outlook by up to $3 billion

Moderna (MRNA) delivered earnings and revenue surprises of -16.78% and 1.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Lags Q3 Earnings Estimates

Short-term supply constraints led Moderna to cut its 2022 revenue outlook to a range of $18 billion to $19 billion.

Moderna tanks 14% after COVID-19 vaccine maker cuts yearly sales outlook and misses 3rd-quarter expectations

Moderna stock plunged Thursday after the company slashed its 2022 outlook, noting supply issues have delayed some of its deliveries. The post Moderna Plummets After Slashing 2022 Outlook Following Massive Quarterly Miss appeared first on Investor's Business Daily.

Moderna Plummets After Slashing 2022 Outlook Following Massive Quarterly Miss

Moderna Inc. shares plunged 11% in premarket trade Thursday, after the COVID vaccine maker posted far weaker-than-expected third-quarter earnings and lowered full-year sales guidance by up to $3 billion.

Moderna stock slides 11.5% premarket after earnings miss by a wide margin and company cuts sales outlook by up to $3 billion

The Covid-19 vaccine maker reported earnings early Thursday that missed Wall Street estimates, while cutting its estimate of total vaccine sales this year by between $2 and $3 billion.

Moderna Stock Tumbles on Earnings Miss, Guidance Cut

The pharmaceutical company said third-quarter revenue fell by nearly a third, with higher costs and a decline in demand for its Omicron-targeting Covid doses hitting its performance.

Moderna Cuts Outlook Amid Supply Constraints

Moderna also missed revenue and earnings expectations for the quarter.

Moderna shares plummet after Covid vaccine maker lowers 2022 sales outlook

Third quarter 2022 revenues of $3.4 billion; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53 Revenue from advance purchase agreements for anticipated delivery in 2022 expected to be $18 to $19 billion, following delay of certain deliveries into 2023 due to short-term supply constraints Primary efficacy analysis from Phase 2 study for personalized cancer vaccine program (mRNA-4157/V940) expected in 4Q22 Phase 3 RSV vaccine efficacy data could read out this winter Phase 3 flu vaccine immunogenicity data expected in 1Q23 Completed $3 billion share repurchase plan announced in February 2022; commenced August 2022 $3 billion share repurchase program CAMBRIDGE, MA / ACCESSWIRE / November 3, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the third quarter of fiscal year 2022. "Today's earnings continue to show strong corporate momentum.

Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates

A rival drugmaker sees higher COVID-related sales ahead.

Why Moderna Stock Rose Today

CAMBRIDGE, MA / ACCESSWIRE / November 1, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222 (Spikevax Bivalent Original/Omicron BA.4-5) in adults 18 years and older.

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Amazon

Teladoc

The future looks bright for these companies.

3 Beaten-Down Growth Stocks That Could Crush the Market

The biotech's promising drug pipeline could drive further gains for shareholders.

News for Moderna Stock (MRNA)